Accurate measurement of cancer recurrence using liquid biopsies
We are a Dutch health-tech startup founded in 2018 by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses.
Cyclomics has developed CyclomicsSeq:
CyclomicsSeq is a novel ctDNA detection assay based on the latest long-read sequencing platforms
Our new diagnostic kit will disrupt the cancer diagnostics market a by enabling fast and reliable results. Delivering superior performance to standard radio-logical and/ physical examination alone
Near 100% accuracy
In contrast to available ctDNA-based methods, CyclomicsSeq ensures that even a single ctDNA molecule present in blood can be detected and red.
each sequencing-read is processed by state of the art bioinformatics and AI platform which leverages the repetitive structure of the concatemers to remove noise and errors thus delivering super-accurate results.
Cyclomics has developed a ground-breaking solution that enables reliable, fast and ultra- sensitive detection of cancer recurrence. This is achieved by detection of ctDNA, a reliable biomarker for determining presence or absence of cancer, which can be non-invasively obtained from a blood sample (liquid biopsy). Since 90% of HNC patients carry specific oncogenic DNA mutations in the gene TP53, the first application of this novel technology is focused on recurring HNC. To this end, Cyclomics is developing CyclomicsSeq TP53: an in vitro diagnostic (IVD) kit integrating an innovative sequencing methodology and state-of- the-art analysis software package. The IVD is designed to seamlessly integrate into existing clinical workflows while providing superior diagnostics for clinical decision making. In the long-term, we will expand the Cyclomics’ solution to other cancer types harboring TP53 mutations.
Cyclomics uses proprietary DNA adapters (backbones) and enzymes blends to capture ctDNA molecules and circularize them. The circular DNA is then amplified by Rolling Circle Amplification (RCA), this process generates long DNA concatemers that are sequenced using long-read sequencing technology. Finally, each sequencing-read is processed by state of the art bioinformatics and AI platform which leverages the repetitive structure of the concatemers to remove noise and errors thus delivering super-accurate results.
We are driven by values
Its our team that make our solutions work.